Contact
Contact Us
Please contact us if you’d like to learn more or if you’re interested in a potential collaboration.
Address
Neutrolis, Inc.
1 Broadway
Cambridge, MA 02142
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body.
Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases.
Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and is supported by seasoned business leaders. The company’s pipeline includes NTR-441 and NTR-452 that effectively removes NETs and halt their pathologic effects.
Dr. Fox is an immunologist trained at Max Planck Institute and Harvard Medical School. Before co-founding and transitioning into Neutrolis, Toby was a Principal Investigator at University Medical Center Hamburg-Eppendorf. Toby is one of the most cited researchers in the field of NETs with important contributions characterizing the formation and clearance of NETs as well as their implications in vascular diseases and organ injuries.
Dr. Hakkim is an immunologist trained at Max Planck Institute and Harvard Medical School. Abdul’s PhD thesis was the first to report on the biology and implications of NETs in autoimmunity. At Harvard, Abdul worked on genetics of innate immunity and co-founded Genma/Artus, a spin-off out of Harvard and now Neutrolis.
Harvard Medical School, Professor of Rheumatology, Immunology and Allergy; Brigham and Women’s Hospital, Director, Lupus program
Dr. Costenbader is the Director of the Lupus Program at Brigham and Women’s Hospital in Boston and Professor of Medicine at Harvard Medical School. She is also the Chair of the Medical-Scientific Advisory Council for the Lupus Foundation of America. Dr. Costenbader as a key opinion leader for lupus and related autoimmune diseases and advises Neutrolis on clinical trial design and execution.
Dr. Kaplan is the Senior Investigator and Chief of Systemic Autoimmunity Branch and Acting Director of Lupus Clinical Trial Unit at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She is a key opinion leader and her research focuses on identifying abnormalities of the neutrophil subpopulation and the role of NETs in lupus and rheumatoid arthritis and other systemic autoimmune diseases.
Yale University School of Medicine, Professor of Pathology; Co-Founder Alexion Pharmaceuticals, Inc. (ALXN)
Dr. Madri is a Professor of Pathology at Yale University School of Medicine and co-founder of Alexion Pharmaceuticals Inc., a commercial-stage publicly traded ultra-rare orphan disease drug development company. Dr. Madri brings to Neutrolis extensive experience building a preeminent drug discovery and development organization from the earliest stages through launch of multiple commercial products. Dr. Madri also brings a deep understanding of the biological mechanism of inflammation and autoimmune disorders and serves on the editorial boards of numerous scientific journals.
Parexel Biotech, SVP and Global Lead, Immunology and Inflammation
Dr. Reiff is a senior vice president and the global lead for the Immunology and Inflammation franchise at Parexel, the global clinical research organization. He is an Emeritus Professor of Pediatrics at Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California and the former Head of the Division of Rheumatology at Children's Hospital Los Angeles. Dr. Reiff received his medical degree from University Medical School in Freiburg, Germany. He completed a research fellowship in the Division of Rheumatology and Bone Marrow Transplantation at Children’s Hospital Los Angeles and a fellowship in pediatric rheumatology at University Children’s Hospital in Freiburg. Dr. Reiff is board-certified in pediatrics and pediatric rheumatology by the European Union and the American Board of Pediatrics. Dr. Reiff assists Neutrolis with clinical development of its therapeutic programs.
Dr. Voll is the Director of the Department of Rheumatology at the University of Freiburg and brings to Neutrolis extensive clinical expertise in autoimmune disorders. Dr. Voll’s research focuses on apoptotic cell death in systemic lupus erythematosus (SLE) and the treatment of antibody-mediated diseases.
DNA is a very long chain of nucleic acids that is wound around histone proteins to form chromatin, which is then packed into the nucleus of eukaryotic cells. Normally, DNA encodes proteins and the instructions needed to make cells function, but it has an additional function within our immune system. Neutrophils, the most abundant immune cells in the body, can expel their long chromatin fibers to form neutrophils extracellular traps (NETs), which activate multiple immune pathways that are implicated in many autoimmune and inflammatory diseases.
The balance between NETs formation and clearance is pivotal for maintaining homeostasis. As a result of persistent inflammation, NETs formation overwhelms the natural clearance mechanisms leading to an accumulation of NETs that exacerbates systemic immune response and end-organ damage. To date, NETs treatment strategies have predominantly focused on inhibiting the creation of NETs, a mechanism, which is conserved and highly biologically redundant.
March 9, 2017
March 9 2011
March 9, 2010
February 9, 2010
March 9 2007
*Note: Dr. Toby Fox publishes under his birth name Tobias Fuchs
Systemically active engineered DNASE1L3
Locally active engineered DNASE1L3
Several therapeutic programs are in development leveraging the robust exDNASE™ platform
Lupus is a systemic autoimmune disease that is characterized by autoantibodies against DNA and inflammation in the joints, skin, kidneys, brain, heart and lungs.
Acute respiratory distress syndrome (ARDS) occurs when the lungs are severely injured, often by infection or trauma, which causes fluid to leak into the lungs, making it difficult to get oxygen into the bloodstream.
Neutrolis is developing therapies for additional undisclosed neutrophil-driven conditions.
Indications
Lupus is a systemic autoimmune disease that is characterized by autoantibodies against DNA and inflammation in the joints, skin, kidneys, brain, heart and lungs.
Acute respiratory distress syndrome (ARDS) occurs when the lungs are severely injured, often by infection or trauma, which causes fluid to leak into the lungs, making it difficult to get oxygen into the bloodstream.
Neutrolis is developing therapies for additional undisclosed neutrophil-driven conditions.
August 3, 2020
September 27, 2019
November 27, 2017
Neutrolis, Inc.
1 Broadway
Cambridge, MA 02142
©2020, Neutrolis. All Rights Reserved.
Neutrophil Scientific Illustrations: Gary Carlson